Amantadine improves gait in PD patients with STN stimulation

Autores
Chan, Hiu Fai; Kukkle, Prashanth L.; Merello, Marcelo Jorge; Lim, Shen Yang; Poon, Yu Yan; Moro, Elena
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
In advanced Parkinson´s disease (PD), axial symptoms such as speech, gait, and balance impairment often become levodopa-unresponsive and they are difficult to manage, even in patients with subthalamic nucleus deep brain stimulation (STN-DBS). We anecdotally observed that oral administration of amantadine was very effective in treating both residual and stimulation-induced axial symptoms after bilateral STN-DBS in one PD patient. Therefore, we conducted a prospective multicenter observational study to evaluate the effects of amantadine on speech, gait and balance in PD patients with STN-DBS and incomplete axial benefit. Primary outcomes were changes in speech (UPDRS III, item 18), gait (item 29) and postural stability (item 30) with amantadine treatment compared to baseline. Secondary outcome was the patients´ subjective scoring of axial symptoms with amantadine compared to baseline. Forty-six PD patients with STN-DBS were enrolled in the study and followed for 10.35 ± 8.21 months (median: 9.00; range: 1-31). The mean daily dose of amantadine was 273.44 ± 47.49 mg. Gait scores significantly improved (from 1.51 ± 0.89 to 1.11 ± 0.92, P = 0.015) with amantadine treatment, whereas postural stability and speech scores were similar before and after treatment. Thirty-five (76.1%) patients reported subjective improvement in speech, gait or balance with amantadine, whereas thirty (65.2%) patients reported improvement in gait and balance. In conclusion, our data suggest that amantadine may have new beneficial effects on axial symptoms in PD patients with STN-DBS.
Fil: Chan, Hiu Fai. University of Toronto; Canadá. Queen Elizabeth Hospital; Hong Kong
Fil: Kukkle, Prashanth L.. University of Toronto; Canadá
Fil: Merello, Marcelo Jorge. Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Lim, Shen Yang. University of Malaya; Malasia
Fil: Poon, Yu Yan. University of Toronto; Canadá
Fil: Moro, Elena. Universite Joseph Fourier; Francia
Materia
Gait
Speech
Deep Brain Stimulation
Balance
Amantadine
Parkinson'S Disease
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/23878

id CONICETDig_ab237343a4b1cce95cbb3f564146a6bf
oai_identifier_str oai:ri.conicet.gov.ar:11336/23878
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Amantadine improves gait in PD patients with STN stimulationChan, Hiu FaiKukkle, Prashanth L.Merello, Marcelo JorgeLim, Shen YangPoon, Yu YanMoro, ElenaGaitSpeechDeep Brain StimulationBalanceAmantadineParkinson'S Diseasehttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3In advanced Parkinson´s disease (PD), axial symptoms such as speech, gait, and balance impairment often become levodopa-unresponsive and they are difficult to manage, even in patients with subthalamic nucleus deep brain stimulation (STN-DBS). We anecdotally observed that oral administration of amantadine was very effective in treating both residual and stimulation-induced axial symptoms after bilateral STN-DBS in one PD patient. Therefore, we conducted a prospective multicenter observational study to evaluate the effects of amantadine on speech, gait and balance in PD patients with STN-DBS and incomplete axial benefit. Primary outcomes were changes in speech (UPDRS III, item 18), gait (item 29) and postural stability (item 30) with amantadine treatment compared to baseline. Secondary outcome was the patients´ subjective scoring of axial symptoms with amantadine compared to baseline. Forty-six PD patients with STN-DBS were enrolled in the study and followed for 10.35 ± 8.21 months (median: 9.00; range: 1-31). The mean daily dose of amantadine was 273.44 ± 47.49 mg. Gait scores significantly improved (from 1.51 ± 0.89 to 1.11 ± 0.92, P = 0.015) with amantadine treatment, whereas postural stability and speech scores were similar before and after treatment. Thirty-five (76.1%) patients reported subjective improvement in speech, gait or balance with amantadine, whereas thirty (65.2%) patients reported improvement in gait and balance. In conclusion, our data suggest that amantadine may have new beneficial effects on axial symptoms in PD patients with STN-DBS.Fil: Chan, Hiu Fai. University of Toronto; Canadá. Queen Elizabeth Hospital; Hong KongFil: Kukkle, Prashanth L.. University of Toronto; CanadáFil: Merello, Marcelo Jorge. Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Lim, Shen Yang. University of Malaya; MalasiaFil: Poon, Yu Yan. University of Toronto; CanadáFil: Moro, Elena. Universite Joseph Fourier; FranciaElsevier2013-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/23878Chan, Hiu Fai; Kukkle, Prashanth L.; Merello, Marcelo Jorge; Lim, Shen Yang; Poon, Yu Yan; et al.; Amantadine improves gait in PD patients with STN stimulation; Elsevier; Parkinsonism & Related Disorders; 19; 3; 3-2013; 316-3191353-8020CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S1353802012004385info:eu-repo/semantics/altIdentifier/doi/10.1016/j.parkreldis.2012.11.005info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:40:14Zoai:ri.conicet.gov.ar:11336/23878instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:40:14.274CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Amantadine improves gait in PD patients with STN stimulation
title Amantadine improves gait in PD patients with STN stimulation
spellingShingle Amantadine improves gait in PD patients with STN stimulation
Chan, Hiu Fai
Gait
Speech
Deep Brain Stimulation
Balance
Amantadine
Parkinson'S Disease
title_short Amantadine improves gait in PD patients with STN stimulation
title_full Amantadine improves gait in PD patients with STN stimulation
title_fullStr Amantadine improves gait in PD patients with STN stimulation
title_full_unstemmed Amantadine improves gait in PD patients with STN stimulation
title_sort Amantadine improves gait in PD patients with STN stimulation
dc.creator.none.fl_str_mv Chan, Hiu Fai
Kukkle, Prashanth L.
Merello, Marcelo Jorge
Lim, Shen Yang
Poon, Yu Yan
Moro, Elena
author Chan, Hiu Fai
author_facet Chan, Hiu Fai
Kukkle, Prashanth L.
Merello, Marcelo Jorge
Lim, Shen Yang
Poon, Yu Yan
Moro, Elena
author_role author
author2 Kukkle, Prashanth L.
Merello, Marcelo Jorge
Lim, Shen Yang
Poon, Yu Yan
Moro, Elena
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Gait
Speech
Deep Brain Stimulation
Balance
Amantadine
Parkinson'S Disease
topic Gait
Speech
Deep Brain Stimulation
Balance
Amantadine
Parkinson'S Disease
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv In advanced Parkinson´s disease (PD), axial symptoms such as speech, gait, and balance impairment often become levodopa-unresponsive and they are difficult to manage, even in patients with subthalamic nucleus deep brain stimulation (STN-DBS). We anecdotally observed that oral administration of amantadine was very effective in treating both residual and stimulation-induced axial symptoms after bilateral STN-DBS in one PD patient. Therefore, we conducted a prospective multicenter observational study to evaluate the effects of amantadine on speech, gait and balance in PD patients with STN-DBS and incomplete axial benefit. Primary outcomes were changes in speech (UPDRS III, item 18), gait (item 29) and postural stability (item 30) with amantadine treatment compared to baseline. Secondary outcome was the patients´ subjective scoring of axial symptoms with amantadine compared to baseline. Forty-six PD patients with STN-DBS were enrolled in the study and followed for 10.35 ± 8.21 months (median: 9.00; range: 1-31). The mean daily dose of amantadine was 273.44 ± 47.49 mg. Gait scores significantly improved (from 1.51 ± 0.89 to 1.11 ± 0.92, P = 0.015) with amantadine treatment, whereas postural stability and speech scores were similar before and after treatment. Thirty-five (76.1%) patients reported subjective improvement in speech, gait or balance with amantadine, whereas thirty (65.2%) patients reported improvement in gait and balance. In conclusion, our data suggest that amantadine may have new beneficial effects on axial symptoms in PD patients with STN-DBS.
Fil: Chan, Hiu Fai. University of Toronto; Canadá. Queen Elizabeth Hospital; Hong Kong
Fil: Kukkle, Prashanth L.. University of Toronto; Canadá
Fil: Merello, Marcelo Jorge. Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Lim, Shen Yang. University of Malaya; Malasia
Fil: Poon, Yu Yan. University of Toronto; Canadá
Fil: Moro, Elena. Universite Joseph Fourier; Francia
description In advanced Parkinson´s disease (PD), axial symptoms such as speech, gait, and balance impairment often become levodopa-unresponsive and they are difficult to manage, even in patients with subthalamic nucleus deep brain stimulation (STN-DBS). We anecdotally observed that oral administration of amantadine was very effective in treating both residual and stimulation-induced axial symptoms after bilateral STN-DBS in one PD patient. Therefore, we conducted a prospective multicenter observational study to evaluate the effects of amantadine on speech, gait and balance in PD patients with STN-DBS and incomplete axial benefit. Primary outcomes were changes in speech (UPDRS III, item 18), gait (item 29) and postural stability (item 30) with amantadine treatment compared to baseline. Secondary outcome was the patients´ subjective scoring of axial symptoms with amantadine compared to baseline. Forty-six PD patients with STN-DBS were enrolled in the study and followed for 10.35 ± 8.21 months (median: 9.00; range: 1-31). The mean daily dose of amantadine was 273.44 ± 47.49 mg. Gait scores significantly improved (from 1.51 ± 0.89 to 1.11 ± 0.92, P = 0.015) with amantadine treatment, whereas postural stability and speech scores were similar before and after treatment. Thirty-five (76.1%) patients reported subjective improvement in speech, gait or balance with amantadine, whereas thirty (65.2%) patients reported improvement in gait and balance. In conclusion, our data suggest that amantadine may have new beneficial effects on axial symptoms in PD patients with STN-DBS.
publishDate 2013
dc.date.none.fl_str_mv 2013-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/23878
Chan, Hiu Fai; Kukkle, Prashanth L.; Merello, Marcelo Jorge; Lim, Shen Yang; Poon, Yu Yan; et al.; Amantadine improves gait in PD patients with STN stimulation; Elsevier; Parkinsonism & Related Disorders; 19; 3; 3-2013; 316-319
1353-8020
CONICET Digital
CONICET
url http://hdl.handle.net/11336/23878
identifier_str_mv Chan, Hiu Fai; Kukkle, Prashanth L.; Merello, Marcelo Jorge; Lim, Shen Yang; Poon, Yu Yan; et al.; Amantadine improves gait in PD patients with STN stimulation; Elsevier; Parkinsonism & Related Disorders; 19; 3; 3-2013; 316-319
1353-8020
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S1353802012004385
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.parkreldis.2012.11.005
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614429507846144
score 13.070432